PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
December 8, 2025Blood

NQO1 modulates CD38 surface expression in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSeungbin HanCVChristina VerbruggenSKShilpa Kurian

Discussion

Loading...

Member takes

Overview

In vitro models reveal NQO1 influences CD38 levels, suggesting targeting it may enhance Daratumumab efficacy in multiple myeloma.

Key Points

  • This research investigates the role of NQO1 in modulating CD38 surface expression in multiple myeloma.
  • Utilized a Sleeping Beauty transposon system to overexpress NQO1 in MM cell lines.
  • Applied dSTORM to measure CD38 surface expression levels.
  • Conducted cytotoxicity assays to assess drug sensitivity with Daratumumab.
  • Analyzed RNA-seq data and Cancer Dependency Map for correlation analysis between NQO1 and CD38 levels.
  • NQO1 overexpression consistently downregulated CD38 in MM cell lines.
  • CD38 cluster density was significantly reduced in NQO1-overexpressing cells compared to wild-type cells.
  • Significant inverse correlation between NQO1 and CD38 expression levels was confirmed in the Cancer Dependency Map.
  • NQO1 overexpression improved survival rates against Daratumumab treatment, indicating reduced efficacy of the therapy.

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6cdhttps://doi.org/10.1182/blood-2025-5718
View Full Paper
Ask AI
Bookmark
Share